Valuation: Arctic Bioscience

Market Cap 85.99M 8.81M 7.71M 7.11M 6.56M 12.46M 840M 12.67M 84.92M 33.35M 414M 33.08M 32.36M 1.42B P/E 2026 *
-3.58x
P/E 2027 * -
Enterprise Value 152M 15.57M 13.62M 12.56M 11.6M 22.02M 1.49B 22.39M 150M 58.94M 732M 58.46M 57.19M 2.51B EV / Sales 2026 *
2.62x
EV / Sales 2027 * -
Free-Float
47.75%
Yield 2026 *
-
Yield 2027 * -
1 day-1.85%
1 week+1.59%
Current month-1.54%
1 month-7.00%
3 months+2.90%
6 months-8.07%
Current year-2.74%
1 week 2.8
Extreme 2.8
3.25
1 month 2.6
Extreme 2.6
3.4
Current year 2.6
Extreme 2.6
3.67
1 year 2.6
Extreme 2.6
4.65
3 years 1.65
Extreme 1.65
16.8
5 years 1.65
Extreme 1.65
21.7
10 years 1.65
Extreme 1.65
32
Manager TitleAgeSince
Chief Executive Officer 60 2010-12-31
Chief Executive Officer 54 2022-02-28
Director of Finance/CFO 47 2022-03-31
Director TitleAgeSince
Director/Board Member 46 2020-12-31
Chairman 68 2015-11-30
Director/Board Member 55 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
23-04-23Buy

Director

943,833 3.8641%
23-04-23Buy

Director

943,833 3.8641%
23-02-22Buy

Chief Technology Officer

11,500 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
-1.85%+1.59%-10.64%-69.47% 8.81M
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.24%-2.76%+22.99%+44.08% 357.39B
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2026 *2027 *
Net sales 58M 5.94M 5.2M 4.79M 4.43M 8.4M 567M 8.54M 57.28M 22.49M 279M 22.31M 21.82M 960M -
Net income -24M -2.46M -2.15M -1.98M -1.83M -3.48M -234M -3.53M -23.7M -9.31M -116M -9.23M -9.03M -397M -
Net Debt 66M 6.76M 5.91M 5.46M 5.04M 9.56M 645M 9.72M 65.18M 25.6M 318M 25.39M 24.83M 1.09B -
Logo Arctic Bioscience
Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
Employees
19
Date Price Change Volume
26-07-10 NOK 3.190 -1.85% 2,053
26-07-09 NOK 3.250 0.00% 0
26-07-08 NOK 3.250 0.00% 0
26-07-07 NOK 3.250 +0.62% 3,725
26-07-06 NOK 3.230 +2.87% 2,930
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Annual profits - Rate of surprise